KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Change in Receivables (2017 - 2023)

Historic Change in Receivables for NovoCure (NVCR) over the last 7 years, with Q3 2023 value amounting to -$2.6 million.

  • NovoCure's Change in Receivables rose 7707.0% to -$2.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$20.3 million, marking a year-over-year decrease of 16514.02%. This contributed to the annual value of -$2.5 million for FY2022, which is 5166.98% up from last year.
  • NovoCure's Change in Receivables amounted to -$2.6 million in Q3 2023, which was up 7707.0% from -$6.9 million recorded in Q2 2023.
  • In the past 5 years, NovoCure's Change in Receivables registered a high of $19.7 million during Q1 2020, and its lowest value of -$14.5 million during Q1 2023.
  • Over the past 5 years, NovoCure's median Change in Receivables value was $2.0 million (recorded in 2019), while the average stood at $1.8 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 86846.76% in 2020, then plummeted by 40923.24% in 2022.
  • NovoCure's Change in Receivables (Quarter) stood at $19.5 million in 2019, then tumbled by 116.44% to -$3.2 million in 2020, then surged by 57.93% to -$1.3 million in 2021, then soared by 379.96% to $3.8 million in 2022, then plummeted by 170.06% to -$2.6 million in 2023.
  • Its last three reported values are -$2.6 million in Q3 2023, -$6.9 million for Q2 2023, and -$14.5 million during Q1 2023.